PE
SRPT icon

Point72 Europe’s Sarepta Therapeutics SRPT Stock Holding History

Point72 Europe’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,983
Closed -$872K – 167
2024
Q3 		$872K Buy
+6,983
New +$965K 0.06% 115
2024
Q1 		– Sell
-321
Closed -$31K – 398
2023
Q4 		$31K Buy
+321
New +$30.8K ﹤0.01% 326

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Point72 Europe's SRPT Position: Q4 2024 in Review

Point72 Europe sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 6,983 shares — an estimated $872K sold.

Point72 Europe first reported a position in SRPT in Q4 2023 and held it in 2 quarters. The position peaked at $872K in Q3 2024. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

  • Point72 Europe reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Point72 Europe sold 6,983 Sarepta Therapeutics shares in Q4 2024, an estimated $872K.
  • Point72 Europe first reported a position in Sarepta Therapeutics in Q4 2023 and held it in 2 quarters.
  • Point72 Europe's Sarepta Therapeutics position peaked at $872K in Q3 2024.
  • 464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Point72 Europe's 13F filing for Q4 2024, filed 14 Feb 2025.